SEARCH

SEARCH BY CITATION

References

  • Anderson T, Miners JO, Veronese ME, Birkett DJ. (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A informs. Br J Clin Pharmacol 38:131137.
  • Anderson GD. (2002) Phenobarbital and other barbiturates: chemistry, biotransformation and pharmacokinetic. In LevyRH, MattsonRH, MeldrumBS, PeruccaE (Eds) Antiepileptic drugs. 4th ed. Lippincott, Philadelphia U.S.A., pp. 496503.
  • Anderson GD, Miller JW. (2002) Benzodiazepines: chemistry, biotransformation and pharmacokinetic. In LevyRH, MattsonRH, MeldrumBS, PeruccaE (Eds) Antiepileptic drugs, 4th ed. Lippincott, Philadelphia U.S.A., pp. 187205.
  • Beyrueter BK, Freitag J, Heers C, Krebsfanger N, Schrfenecker U, Stohr T. (2007) Lacosamide: a review of preclinical properties. CNS Drug Rev. 13:2142.
  • Bialer M, Cloyd JC. (1995) General principles: formulations and routes of administration. In LevyRH, MattsonRH, MeldrumBS (Eds) Antiepileptic drugs. 4th ed. Raven Press, New York, pp. 161178.
  • Bialer M, Johannessen SJ, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. (2002) Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51:3171.
  • Bialer M, Johannessen SJ, Kupferberg HJ, Levy RH, Perucca E, Tomson T. (2004) Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 61:148.
  • Bialer M. (2007) Clinical pharmacology of parenteral use of antiepileptic therapy. Epilepsia 48(suppl 8):4648.
  • Bialer M, Johannessen SJ, Kupferberg HJ, Levy RH, Perucca E, Tomson T. (2007) Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 73:152.
  • Bialer M, Johannessen SJ, Levy RH, Perucca E, Tomson T, White HS. (2009) Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res 83:143.
  • Biton V, Rosenfeld WE, Whitesides J, Fountain NB, Vaiciene N, Rudd GD. (2008) Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 49:418424.
  • Browne TR, Evans JE, Szabo GK, Evans BA, Greenblatt DJ. (1985) Studies with stable isotopes II: phenobarbital pharmacokinetics during monotherapy. J Clin Pharmacol 25:5158.
  • Browne TR, LeDuc B. (1995) Phenytoin: formulations and routes of administration. In LevyRH, MattsonRH, MeldrumBS (Eds) Antiepileptic drugs. 4th ed. Raven Press, New York, pp. 283300.
  • Claassen J, Hirsh LJ, Emerson RG, Mayer SA. (2002) Treatment of refractory status epilepticus with pentobarbital, propopfol and midazolam: a systematic review. Epilepsia 43:146153.
  • Claassen J, Hirsch LJ, Mayer SA. (2003) Treatment of status epilepticus: a survey of neurologists. J Neurol Sci 211:3741.
  • Cloyd JC, Dutta S, Cao G, Walch JK, Collins SD, Granneman GR, The Depacon Study Group. (2003) Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res 53:1927.
  • Devinsky O, Leppik IE, Wilmore LJ, Pellock JM, Dean C, Gates J, Ramsay RE. (1995) Safety of intravenous valproate. Ann Neurol 38:67674.
  • Freedman H, Greenblatt DJ, Peter GR, Metzler CM, Charlton MD, Harmatz JS, Antal AE, Sanborn EC, Francon SF. (1992) Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose plasma concentration, and time. Clin Pharmacol Ther 52:139150.
  • Garzone PD, Kroboth PD. (1989) Pharmacokinetics of the new benzodiazepines. Clin Pharmacokinet 16:337364.
  • Greenblatt DJ, Allen MD, Harmatz JS, Shader R. (1980) Diazepam disposition determinants. Clin Pharmacol Ther 27:301312.
  • Greenblatt DJ. (1981) Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 6:89105.
  • Holtkamp M, Masuhr F, Harms L, Einhaupl KM, Meierkord H, Buchheim K. (2003) The management of refractory generalized convulsive and complex partial status epilepticus in three European countries: a survey among epilepticus and critical care neurologists. J Neurol Neurosurg Psychiatr 74:10951099.
  • International Marketing Service (IMS-HEALTH) (2009). London IMS World Publication.
  • Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, Hamer HM, Rosenow F. (2008) Intravenous levetiracetam in eth treatment of benzodiazepine refectory epilepticus. J Neurol Neuroeserg Psych 79:588589.
  • Krauss G, Ben-Menachem E, Mameniskien R, Vaicine N, Brock M, Whitesides J. (2006) Intravenous lacosamide (SPM 927) as a replacement for oral lacosamide in subjects with partial seizures; a multicenter, open-label, inpatient safety and tolerability trial. AES Abstract Book abstract 2.127.
  • Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. (2004) Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 45(suppl 7):123 (Abstract 1.323).
  • Loscher W, Honack D, Richter A, Schultz H-U, Schurer M, Dusing R, Brewster M. (1995) New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-β-cylcodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to glycofurol-based formulation. Epilepsia 36:255261.
  • Lowenstein DH. (2006) The management of refractory status epilepticus: an update. Epilepsia 47(suppl 1):3540.
  • Lowenstein DH, Cloyd J. (2007) Out of hospital treatment of status epilepticus and prolonged seizures. Epilepsia 48(suppl 8):9698.
  • Naritoku DK, Mueed S. (1999) Intravenous loading of valproate for epilepsy. Clin Neuropharmacol 22:102106.
  • Peters CNA, Pohlmann-Eden B. (2005) Intravenous valproate as an innovative therapy in seizure emergency situation including status epilepticus – experience in 102 adult patients. Seizure 14:164169.
  • Ramel S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethusisen JM, Stobkis A. (2006a) Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablet and multiple-dose pharmacokinetics and tolerability of levetiracetam infusion compared to placebo in healthy subject. Clin Ther 38:734744.
  • Ramel S, Daust A, Otoul C, Toublanc N, Troenaru M, Lu Z, Stobkis A. (2006b) Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47:11281135.
  • Ruegg S, Neagelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. (2008) Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 12:477480.
  • Thummel KE, O’Shea D, Paine MF, Shen DD, Kunzer KL, Perkins JD, Wilkinson GR. (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediaetd metabolism. Clin Pharmacol Ther 59:491502.